General practice

Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study

Hugh Tunstall-Pedoe, Mark Woodward, Roger Tavendale, Richard A' Brook, Mary K McCluskey

Cardiovascular Epidemiology Unit, Ninewells Hospital and Medical School, Dundee DD1 9SY Hugh

Hugh Tunstall-Pedoe, professor and director Mark Woodward, senior lecturer in statistical epidemiology Roger Tavendale, biochemist Richard A' Brook, research assistant

Correspondence to: Professor Tunstall-Pedoe h.tunstallpedoe@ dundee.ac.uk

Mary K McCluskey,

research assistant

BMJ 1997;315:722-9

Abstract

Objective: To compare prediction by 27 different factors in men and women of coronary heart disease events, coronary deaths, and deaths from all causes.

Design: Cohort study.

Setting: Scottish population study.

Subjects: In 1984-7 random sampling of residents aged 40-59 produced 11 629 men and women who generated survey clinic questionnaires, examination findings, and blood and urine specimens.

Main outcome measures: Subsequent death, coronary artery surgery, and myocardial infarction. Risks were calculated for each category of factor or fifth of continuous variables. 27 factors were ranked by descending age adjusted hazard ratio of the top to bottom class in each factor, by sex and end point. **Results:** Follow up averaged 7.6 years, during which the 5754 men had 404 coronary events, 159 coronary deaths, and 383 deaths and the 5875 women 177, 47, and 208 respectively. The rankings for factors for the three end points were mainly similar in men and women, although hazard ratios were often higher in women. Classical risk factors ranked better for predicting coronary risk than newer ones. Yet strong prediction of coronary risk was no guarantee of significant prediction of all cause mortality. Findings included an anomalous coronary protective role for type A behaviour in women; raised plasma fibrinogen

potassium to all cause mortality. **Conclusions:** These initial unifactorial rankings and comparisons must be interpreted with caution until potential interaction, confounding, and problems of measurement and causation are further explored.

unexpectedly powerful protective relation of dietary

as a strong predictor of all end points; and an

Introduction

With few exceptions, ^{1,3} studies identifying risk factors for coronary heart disease have focused on men, ^{4,9} with their higher incidence rates, ¹⁰ yet women live longer and lifetime risk is almost equal. ¹¹ All cause mortality is now a standard end point in intervention studies but relatively neglected in studies of risk factors. There is a need for studies which include standardised measurement of lifestyle and coronary risk factors in

men and women and where all cause mortality is reported alongside coronary end points.

The Scottish heart health study¹² began in 1984, when Scotland was in the premier league for death from coronary heart disease in both men and women. It reported lifestyle and risk factor status for representative samples of men and women across Scotland¹³ ¹⁴ and showed how regional variations in risk factors correlated with mortality from coronary heart disease.¹⁵

We always intended to see how well older and new factors compared in predicting coronary risk, 12 and after eight years' follow up we now compare 27 factors in the two sexes for three end points—major coronary events (non-fatal myocardial infarction, death from coronary heart disease, or coronary artery surgery), deaths from coronary heart disease, and all deaths.

Methods

Recruitment-Twenty five districts of Scotland were visited in two contrasting seasons in November 1984 to October 1987. General practitioners were recruited randomly and their patients enumerated in the eight five year age-sex bands 40-59. A constant percentage in each district band was selected by random sampling. $^{\mbox{\tiny 12 16}}$ In 23 districts the target total was 450people from 10 general practitioners but the Edinburgh and north Glasgow MONICA (monitoring trends and determinants in cardiovascular disease) population surveys¹⁷ each included 30 general practitioners and 800 participants aged 40-59. Joint letters were sent out from survey and practice enclosing appointments for local clinics, plus a 20 page personal health record for self completion. This included several classical cardiovascular questionnaires, 18 a food frequency questionnaire adapted from Caerphilly, 19 and the Bortner questionnaire for type A personality.20

Survey clinic procedures—Clinics were run by survey nurses. Participants reported without fasting and progressed through three stations. Firstly, after removing shoes and outer clothing, they were weighed, had their height measured, and gave informed consent, including to follow up of medical records. The questionnaire was checked. Blood pressure was measured twice by random zero sphygmomanometer

seated after five minutes' rest. Station two recorded a 12 lead electrocardiogram and measured expired air carbon monoxide. At station three venepuncture and a subcutaneous fat biopsy were performed and a 2.5 litre container for 24 hour urine collection was supplied.¹²

Processing and quality control—Serum was separated within two hours and chilled at 4°C while plasma was separated immediately and stored at -20°C before both were transferred within five days to Dundee. Urine collections were weighed and analysed for electro-

lytes and for creatinine. The latter and most serum analyses were analysed in duplicate shortly after reaching Dundee. Serum cotinine and adipose tissue fatty acids were analysed subsequently by gas chromatography. After storage at -40° C plasma specimens were assayed in Glasgow by coagulometer for fibrinogen. Survey and laboratory procedures including lipid analyses were standardised on the World Health Organisation's MONICA protocol and its lipid laboratory. Electrocardiograms were coded by two




Fig 1 Ranking of risk factors for all coronary events in men and women by age adjusted hazard ratios between highest and lowest category (fifths unless indicated). *Factors with fewer than five classes

Fig 2 Ranking of risk factors for all cause mortality in men and women by age adjusted hazard ratios between highest and lowest category (fifths unless indicated). *Factors with fewer than five classes

Table 1 Numbers of people at risk and numbers experiencing a qualifying end point event during follow up

| | | | Age group | | |
|------------------------------|-------|-------|-----------|-------|----------|
| | 40-44 | 45-49 | 50-54 | 55-59 | All ages |
| Men: | | | | | |
| All people at baseline | 1398 | 1370 | 1521 | 1465 | 5754 |
| All coronary heart disease* | 66 | 68 | 106 | 164 | 404 |
| Fatal coronary heart disease | 21 | 15 | 45 | 78 | 159 |
| Deaths from all causes | 42 | 54 | 110 | 177 | 383 |
| Nomen: | | | | | |
| All persons at baseline | 1503 | 1438 | 1521 | 1413 | 5875 |
| All coronary heart disease* | 17 | 32 | 43 | 85 | 177 |
| Fatal coronary heart disease | 0 | 5 | 13 | 29 | 47 |
| Deaths from all causes | 21 | 32 | 54 | 101 | 208 |

^{*}Endpoint of all coronary heart disease includes coronary death, or coronary artery surgery, or non-fatal definite or possible myocardial infarction but the latter only qualifies in the absence of a previous history of myocardial infarction.

observers with a third adjudicating discrepancies.²³ Questionnaires were part coded by nurses before transfer to Dundee, where they were checked, double coded, keyed, and verified on microcomputer. Data underwent range and logic checks and were assembled by individual anonymous code on the mainframe. Personal identifiers were stored elsewhere.

Follow up-Participants were flagged on the Scottish NHS Register, which forwarded copies of death certificates. The Scottish heart health study register of participants, updated with information from health

boards, was run against a central file of hospital discharge data by the information and statistics division of the Scottish Common Services Agency, generating a list of all hospital admissions from before the study began to the end of 1993,24 which was also used as the cut point for mortality follow up.

End points-Case notes were requested for all hospital episodes of myocardial infarction and other emergency admissions for coronary heart disease. These were extracted and coded according to MONICA project criteria as definite, possible, or no myocardial infarction, the first two categories being included as end points.^{10 22 25} Hospital diagnoses of coronary artery surgery (coronary artery bypass grafts or percutaneous transluminal coronary angioplasty) were accepted without verification, as were out of hospital coronary deaths, as further inquiry in the Scottish MONICA project rarely changes the diagnosis.25 We report three overlapping end points. Participants progressing to myocardial infarction, coronary artery surgery, or death from coronary disease qualified for all coronary heart disease, barring those few who had non-fatal recurrence of a prerecruitment myocardial infarction. Two fatal end points were deaths from coronary heart disease and deaths from all causes.

Table 2 Age adjusted hazard ratios for two and three class categorical data

| | | | | Missing | | | | Missing | | |
|---------------------|---------------------|------------------|----------|---------------------------------------|---------|--------|---------|----------|----------------------------------|---------|
| Class | 1 | 2 | 3 | Multiplicative constant (95% CI) | P value | 1 | 2 | 3 | Multiplicative constant (95% CI) | P value |
| Housing tenure (ov | vned/rented) | | | | | | | | | |
| Tenure | Own | Rent | | | | Own | Rent | | | |
| % | 53.5 | 46.5 | | 19 | | 51.4 | 48.6 | | 25 | |
| All CHD | 1 | 1.48 | | 1.48 (1.21 to 1.80) | *** | 1 | 2.64 | | 2.64 (1.89 to 3.68) | *** |
| CHD deaths | 1 | 1.56 | | 1.56 (1.13 to 2.14) | ** | 1 | 2.42 | | 2.42 (1.28 to 4.59) | ** |
| All deaths | 1 | 1.55 | | 1.55 (1.26 to 1.90) | *** | 1 | 2.12 | | 2.12 (1.58 to 2.84) | *** |
| Diabetes mellitus | (no/yes) | | | | | | | | | |
| Diabetes | No | Yes | | | | No | Yes | | | |
| % | 98.4 | 1.6 | | 65 | | 98.5 | 1.5 | | 87 | |
| All CHD | 1 | 1.31 | | 1.31 (0.67 to 2.53) | NS | 1 | 2.91 | | 2.91 (1.43 to 5.92) | ** |
| CHD deaths | 1 | 2.14 | | 2.14 (0.95 to 4.85) | BS | 1 | 4.03 | | 4.03 (1.25 to 12.99) | * |
| All deaths | 1 | 2.08 | | 2.08 (1.22 to 3.55) | ** | 1 | 1.50 | | 1.50 (0.62 to 3.66) | NS |
| Menopausal status | (no/yes) | | | · · · · · · · · · · · · · · · · · · · | | | | | | |
| Menopause | | | | | | No | Yes | | | |
| % | | | | | | 42.3 | 57.7 | | 36 | |
| All CHD | _ | _ | | | | 1 | 1.48 | | 1.48 (0.92 to 2.40) | NS |
| CHD deaths | _ | _ | | | | 1 | 1.07 | | 1.07 (0.36 to 3.19) | NS |
| All deaths | _ | _ | | | | 1 | 1.35 | | 1.35 (0.86 to 2.11) | NS |
| Cigarette smoking | (never/ex/current | t smoker) | | | | | | | | |
| Status | Never | Ex | Current | | | Never | Ex | Current | | |
| % | 25.7 | 34.8 | 39.5 | 41 | | 41.6 | 20.2 | 38.2 | 39 | |
| All CHD | 1 | 1.38 | 2.02 | 1.43 (1.25 to 1.63) | *** | 1 | 1.16 | 2.70 | 1.69 (1.42 to 2.02) | *** |
| CHD deaths | 1 | 1.54 | 2.50 | 1.60 (1.28 to 1.98) | *** | 1 | 1.73 | 3.24 | 1.81 (1.27 to 2.57) | *** |
| All deaths | 1 | 1.54 | 2.34 | 1.53 (1.33 to 1.75) | *** | 1 | 1.56 | 2.80 | 1.68 (1.43 to 1.99) | *** |
| Physical inactivity | in work (active/a | verage/inactive) | | | | | | | | |
| Status | Active | Average | Inactive | | | Active | Average | Inactive | | |
| % | 42.4 | 44.4 | 13.2 | 62 | | 47.4 | 48.1 | 4.5 | 25 | |
| All CHD | 1 | 1.18 | 1.35 | 1.17 (1.01 to 1.34) | * | 1 | 1.13 | 2.45 | 1.35 (1.05 to 1.74) | * |
| CHD deaths | 1 | 1.57 | 1.84 | 1.39 (1.11 to 1.34) | ** | 1 | 0.82 | 3.79 | 1.44 (0.88 to 2.35) | NS†† |
| All deaths | 1 | 1.32 | 1.55 | 1.26 (1.09 to 1.45) | ** | 1 | 1.10 | 3.50 | 1.54 (1.22 to 1.94) | ***†† |
| Leisure physical in | nactivity (active/a | verage/inactive) | | | | | | | | |
| Status | Active | Average | Inactive | | | Active | Average | Inactive | | |
| % | 22.8 | 59.0 | 18.2 | 27 | | 19.2 | 62.1 | 18.7 | 23 | |
| All CHD | 1 | 1.11 | 1.45 | 1.21 (1.03 to 1.41) | * | 1 | 1.26 | 1.51 | 1.23 (0.96 to 1.56) | BS |
| CHD deaths | 1 | 1.28 | 2.07 | 1.46 (1.14 to 1.87) | ** | 1 | 0.78 | 2.22 | 1.68 (1.04 to 2.70) | *† |
| All deaths | 1 | 1.08 | 1.66 | 1.31 (1.11 to 1.54) | ** | 1 | 0.99 | 2.20 | 1.61 (1.29 to 2.02) | ***# |

CHD=coronary heart disease. Log linear significance testing: NS=not significant (P \geq 0.10), BS=borderline (0.05 \leq P < 0.1), *=significant (0.01 \leq P< 0.05), **=highly significant (0.001 \leq P<0.01), ***=very highly significant (P<0.001). Residual non-linear significance testing uses † instead of *.

Statistical procedures

Cox's proportional hazards model²⁶ allows for the different follow up times from attendance at the initial clinic until the end of 1993. Survival was counted to the first qualifying event. Loss to follow up for coronary end points occurred through death from a non-coronary cause and for all end points through emigration.

For continuously distributed factors the population was partitioned into fifths, up to and including the 20th, 40th, 60th, and 80th centiles. The tables specify

the quintile values, but also those of the 1st and 99th centiles, rather than extreme readings. Values of zero identified the lowest class for alcohol consumption and for serum cotinine concentration; partitioning at and below the 25th, 50th, and 75th centiles classified others with positive values into the four remaining classes. For categorical factors class sizes were uneven and their number, 2-5, implicit.

For each factor, end point, and sex, after age adjustment, the risk in the lowest class was set at unity and the

Table 3 Age adjusted hazard ratios for five class discontinuous factors

| | | | Men | | | Women | | | | | | | | |
|----------------|---|---|--|--|---|-----------------------------------|---|--|---|--|---|--|---|--|
| | | | | | Missing | | | | | | | Missing | | |
| 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | |
| y heart diseas | е | | | | | | | | | | | | | |
| None | Rose+ | ECG+ | Angina | MI | | | None | Rose+ | ECG+ | Angina | MI | | | |
| 78.5 | 6.4 | 6.9 | 3.4 | 4.8 | 134 | | 79.1 | 7.7 | 8.2F | 3.4 | 1.6 | 135 | | |
| 1 | 1.57 | 2.69 | 5.83 | NA | 1.75 (1.60 to 1.92) | *** | 1 | 1.75 | 2.67 | 7.31 | NA | 1.86 (1.63 to 2.12) | *** | |
| 1 | 1.90 | 3.783 | 5.41 | 8.04 | 1.70 (1.54 to 1.87) | *** | 1 | 1.88 | 5.44 | 3.77 | 25.32 | 2.10 (1.74 to 2.54) | *** | |
| 1 | 1.53 | 2.15 | 2.36 | 3.39 | 1.36 (1.27 to 1.46) | *** | 1 | 1.60 | 2.19 | 2.21 | 5.23 | 1.44 (1.29 to 1.60) | *** | |
| pe A personali | ty) | | | | | | | | | | | | | |
| ≤ 134 | 135- | 160- | 179- | ≥203 | | | ≤ 138 | 139- | 162- | 178- | ≥ 199 | | | |
| 19.9 | 20.1 | 19.8 | 20.0 | 20.0 | 481 | | 19.9 | 20.5 | 19.6 | 20.3 | 19.8 | 670 | | |
| 1 | 1.08 | 0.87 | 0.78 | 1.04 | 0.98 (0.91 to 1.05) | NS | 1 | 0.52 | 0.64 | 0.57 | 0.38 | 0.82 (0.73 to 0.93) | ** | |
| 1 | 1.16 | 0.90 | 0.76 | 1.08 | 0.98 (0.87 to 1.10) | NS | 1 | 0.39 | 0.62 | 0.34 | 0.35 | 0.77 (0.60 to 0.99) | * | |
| 1 | 0.86 | 0.69 | 0.73 | 0.74 | 0.92 (0.85 to 0.99) | * | 1 | 0.66 | 0.75 | 0.84 | 0.59 | 0.92 (0.82 to 1.02) | NS | |
| ng/ml) | | | | | | | | | | | | | | |
| 0 | 0.01- | 2.17- | 59.31- | ≥ 285.0 | | | 0 | 0.01- | 1.40- | 14.21- | ≥248.1 | | | |
| 13.9 | 21.5 | 21.5 | 21.5 | 21.6 | 1409 | | 22.5 | 19.4 | 19.3 | 19.5 | 19.3 | 1656 | | |
| 1 | 1.19 | 1.13 | 1.72 | 2.18 | 1.23 (1.13 to 1.35) | *** | 1 | 0.91 | 0.96 | 2.61 | 4.48 | 1.59 (1.38 to 1.83) | *** | |
| 1 | 1.39 | 0.89 | 2.01 | 2.91 | 1.32 (1.14 to 1.54) | *** | 1 | 1.20 | 1.65 | 2.90 | 10.73 | 2.05 (1.46 to 2.87) | *** | |
| 1 | 1.18 | 1.43 | 2.09 | 2.56 | 1.29 (1.18 to 1.42) | *** | 1 | 0.52 | 1.17 | 1.92 | 3.30 | 1.48 (1.30 to 1.68) | ***† | |
| eek) | | | | | | | | | | | | | | |
| 0 | 1-7 | 8-15 | 16-29 | ≥30 | | | 0 | 1-2 | 3-5 | 6-9 | ≥10 | | | |
| 20.0 | 20.4 | 19.7 | 20.1 | 19.7 | 15 | | 38.0 | 414.6 | 17.8 | 14.5 | 15.0 | 22 | | |
| 1 | 1.00 | 0.59 | 0.82 | 0.62 | 0.89 (0.83 to 0.95) | **† | 1 | 0.70 | 0.64 | 0.56 | 0.64 | 0.86 (0.77 to 0.96) | *** | |
| 1 | 0.87 | 0.63 | 0.94 | 0.62 | 0.92 (0.82 to 1.03) | NS | 1 | 0.49 | 0.58 | 0.36 | 0.52 | 0.79 (0.62 to 1.00) | * | |
| 1 | 0.90 | 0.84 | 0.83 | 1.17 | 1.02 (0.95 to 1.10) | NS | 1 | 0.64 | 0.85 | 0.79 | 0.93 | 0.97 (0.88 to 1.07) | NS | |
| | y heart diseas None 78.5 1 1 1 1 pe A personali ≤134 19.9 1 1 1 1 1 1 1 1 2 2 0 2 0 1 1 1 1 1 1 1 1 1 1 1 1 | y heart disease None Rose+ 78.5 6.4 1 1.57 1 1.90 1 1.53 pe A personality ≤ 134 135- 19.9 20.1 1 1.08 1 1.16 1 0.86 ng/ml) 0 0.07- 13.9 21.5 1 1.19 1 1.39 1 1.18 nek 0 1-7 20.0 20.4 1 1.00 1 0.87 | y heart disease None Rose+ ECG+ 78.5 6.4 6.9 1 1.57 2.69 1 1.90 3.783 1 1.53 2.15 pe A personality ≤ 134 135- 160- 19.9 20.1 19.8 1 1.16 0.90 1 0.86 0.69 1 0.86 0.69 1 1.19 1.13 1 1.39 0.89 1 1.18 1.43 20.0 20.4 19.7 1 1.00 0.59 1 0.87 0.63 | 1 2 3 4 y heart disease None Rose+ ECG+ Angina 78.5 6.4 6.9 3.4 1 1.57 2.69 5.83 1 1.90 3.783 5.41 1 1.53 2.15 2.36 pe A personality) ≤ 134 135- 160- 179- 19.9 20.1 19.8 20.0 1 1.08 0.87 0.78 1 1.16 0.90 0.76 1 0.86 0.69 0.73 ng/ml) 0 0.01- 2.17- 59.31- 13.9 21.5 21.5 21.5 1 1.19 1.13 1.72 1 1.39 0.89 2.01 1 1.39 0.89 2.01 20.0 20.4 19.7 20.1 20.0 20.4 19.7 20.1 1 1.00 0.59 0.82 20.0 20.4 19.7 20.1 1 1.00 0.59 0.82 1 0.87 0.63 0.94 | y heart disease None Rose+ ECG+ Angina MI 78.5 6.4 6.9 3.4 4.8 1 1.57 2.69 5.83 NA 1 1.90 3.783 5.41 8.04 1 1.53 2.15 2.36 3.39 pe A personality ≤ 134 135- 160- 179- ≥ 203 19.9 20.1 19.8 20.0 20.0 1 1.08 0.87 0.78 1.04 1 1.16 0.90 0.76 1.08 1 0.86 0.69 0.73 0.74 ng/ml) 0 0.01- 2.17- 59.31- ≥ 285.0 1 1.19 1.13 1.72 2.18 1 1.39 0.89 2.01 2.91 1 1.18 1.43 2.09 2.56 sek 0 1-7 8-15 16-29 ≥ 30 20.0 20.4 19.7 20.1 19.7 1 1.00 0.59 0.82 0.62 1 0.87 0.63 0.94 0.62 | None Rose+ ECG+ Angina MI | None Rose+ ECG+ Angina MI MI MI MI MI MI MI M | 1 2 3 4 5 Missing (95% Cl) P value 1 y heart disease None Rose+ ECG+ Angina MI None None 78.5 6.4 6.9 3.4 4.8 134 1 1 1.57 2.69 5.83 NA 1.75 (1.60 to 1.92) 1 1 1.90 3.783 5.41 8.04 1.70 (1.54 to 1.87) 1 1 1.93 2.15 2.36 3.39 1.36 (1.27 to 1.46) 1 1 1.53 2.15 2.36 3.39 1.36 (1.27 to 1.46) 1 1 1.53 2.15 2.36 3.99 1.36 (1.27 to 1.46) 1 1 1.53 2.15 2.60 2.00 481 19.99 1 1.08 0.87 0.78 1.04 0.98 (0.91 to 1.05) NS 1 <t< td=""><td>1 2 3 4 5 Missing Multiplicative constant (95% ci) P value 1 2 y heart disease None Rose+ ECG+ Angina MI None Rose+ None Rose+ 78.5 6.4 6.9 3.4 4.8 134 .*** 1 1.75 1 1.57 2.69 5.83 NA 1.75 (1.60 to 1.92) **** 1 1.75 1 1.90 3.783 5.41 8.04 1.70 (1.54 to 1.87) **** 1 1.88 1 1.53 2.15 2.36 3.39 1.36 (1.27 to 1.46) **** 1 1.60 pe A personality 1 1.53 2.05 2.03 2.00 481 19.9 20.5 19.9 20.1 19.8 20.0 20.0 481 19.9 20.5 1 1.08 0.87 0.78 1.04 0.98 (0.91 to 1.05) NS</td><td> None Rose ECG Angina MI 1.57 Rose ECG Angina MI 1.57 Rose Rose ECG Rose R</td><td> None Rose+ ECG+ Angina MI MI MI MI MI MI MI M</td><td> None Rose ECG Angina Missing None None None Rose ECG None None None None Rose Rose None None </td><td> Missista Missista</td></t<> | 1 2 3 4 5 Missing Multiplicative constant (95% ci) P value 1 2 y heart disease None Rose+ ECG+ Angina MI None Rose+ None Rose+ 78.5 6.4 6.9 3.4 4.8 134 .*** 1 1.75 1 1.57 2.69 5.83 NA 1.75 (1.60 to 1.92) **** 1 1.75 1 1.90 3.783 5.41 8.04 1.70 (1.54 to 1.87) **** 1 1.88 1 1.53 2.15 2.36 3.39 1.36 (1.27 to 1.46) **** 1 1.60 pe A personality 1 1.53 2.05 2.03 2.00 481 19.9 20.5 19.9 20.1 19.8 20.0 20.0 481 19.9 20.5 1 1.08 0.87 0.78 1.04 0.98 (0.91 to 1.05) NS | None Rose ECG Angina MI 1.57 Rose ECG Angina MI 1.57 Rose Rose ECG Rose R | None Rose+ ECG+ Angina MI MI MI MI MI MI MI M | None Rose ECG Angina Missing None None None Rose ECG None None None None Rose Rose None None | Missista Missista | |

 $CHD = coronary\ heart\ disease.\ ECG = electrocardiogram.\ MI = myocardial\ infarction.\ See\ footnote\ to\ table\ 1\ for\ P\ values.$

Table 4 Age adjusted hazard ratios by fifths of physical attributes

| Men | | | | | | | | | Women | | | | | | | | |
|-------------------|----------------------|--------|------|------|------|------|-------------------------------------|---------|-------|------|------|------|------|------|-------------------------------------|---------|--|
| Centile | 1 | 20 | 40 | 60 | 80 | 99 | Missing | | 1 | 20 | 40 | 60 | 80 | 99 | Missing | | |
| Fifth | | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | |
| Height (m) | | | | | | | | | | | | | | | | | |
| | 1.57F | 1.67 | 1.71 | 1.74 | 1.78 | 1.88 | 27 | | 1.46 | 1.55 | 1.58 | 1.61 | 1.65 | 1.75 | 9 | | |
| All CHD | | 1 | 0.94 | 0.76 | 0.78 | 0.66 | 0.90 (0.84 to 0.97) | ** | | 1 | 0.65 | 0.62 | 0.61 | 0.63 | 0.89 (0.80 to 0.98) | * | |
| CHD deaths | | 1 | 0.92 | 0.75 | 0.69 | 0.80 | 0.93 (0.83 to 1.03) | NS | | 1 | 0.82 | 0.82 | 0.88 | 0.91 | 0.98 (0.80 to 1.20) | NS | |
| All deaths | | 1 | 1.06 | 0.76 | 0.78 | 0.78 | 0.92 (0.86 to 0.99) | * | | 1 | 0.86 | 1.11 | 1.10 | 0.84 | 1.00 (0.91 to 1.10) | NS | |
| Weight (kg) | | | | | | | | | | | | | | | | | |
| | 53 | 68 | 74 | 80 | 87 | 111 | 6 | | 44 | 56 | 61 | 66 | 74 | 103 | 3 | | |
| All CHD | | 1 | 1.01 | 1.23 | 1.12 | 1.40 | 1.08 (1.01 to 1.16) | * | | 1 | 0.79 | 0.69 | 0.75 | 1.40 | 1.08 (0.97 to 1.20) | NS† | |
| CHD deaths | | 1 | 0.88 | 0.90 | 0.77 | 1.31 | 1.05 (0.94 to 1.18) | NS | | 1 | 0.42 | 0.85 | 0.63 | 1.40 | 1.11 (0.91 to 1.37) | NS | |
| All deaths | | 1 | 0.83 | 0.66 | 0.64 | 0.92 | 0.96 (0.89 to 1.03) | t | | 1 | 0.75 | 0.78 | 0.67 | 1.13 | 1.02 (0.92 to 1.12) | t | |
| Body mass index | (kg/m ²) | | | | | | | | | | | | | | | | |
| | 18.8 | 23.3 | 25.1 | 26.7 | 28.7 | 36.2 | 27 | | 18.0 | 22.1 | 24.0 | 26.0 | 28.9 | 41.1 | 10 | | |
| All CHD | | 1 | 1.71 | 1.47 | 1.52 | 1.97 | 1.12 (1.05 to 1.20) | ** | | 1 | 0.69 | 0.71 | 0.98 | 1.37 | 1.13 (1.01 to 1.25) | * | |
| CHD deaths | | 1 | 1.77 | 1.11 | 1.25 | 1.68 | 1.06 (0.95 to 1.19) | NS | | 1 | 0.40 | 0.29 | 0.68 | 1.20 | 1.13 (0.92 to 1.40) | NS† | |
| All deaths | | 1 | 0.98 | 0.86 | 0.78 | 1.05 | 0.99 (0.92 to 1.06) | NS | | 1 | 0.57 | 0.69 | 0.77 | 0.97 | 1.03 (0.93 to 1.13) | t | |
| Systolic blood pr | essure (mr | n Hg) | | | | | | | | | | | | | | | |
| | 98 | 118 | 127 | 136 | 148 | 190 | 6 | | 95 | 113 | 123 | 133 | 148 | 192 | 6 | | |
| All CHD | | 1 | 1.07 | 1.54 | 1.65 | 2.25 | 1.23 (1.15 to 1.33) | *** | | 1 | 1.22 | 1.38 | 1.84 | 3.10 | 1.35 (1.20 to 1.52) | *** | |
| CHD deaths | | 1 | 0.54 | 1.26 | 0.98 | 1.62 | 1.18 (1.05 to 1.32) | **† | | 1 | 1.65 | 6.48 | 5.08 | 13.1 | 1.76 (1.33 to 2.33) | *** | |
| All deaths | | 1 | 0.77 | 1.20 | 1.13 | 1.43 | 1.12 (1.04 to 1.20) | ** | | 1 | 1.02 | 0.84 | 1.07 | 2.18 | 1.25 (1.12 to 1.39) | ***†† | |
| Diastolic blood p | ressure (m | ım Hg) | | | | | | | | | | | | | | | |
| | 59 | 74 | 80 | 86 | 93 | 115 | 7 | | 58 | 71 | 78 | 83 | 90 | 113 | 7 | | |
| All CHD | | 1 | 1.52 | 1.47 | 1.51 | 2.47 | 1.21 (1.12 to 1.30) | *** | | 1 | 0.98 | 1.13 | 1.08 | 1.85 | 1.17 (1.05 to 1.30) | ** | |
| CHD deaths | | 1 | 1.40 | 1.54 | 1.06 | 2.43 | 1.19 (1.06 to 1.34) | **† | | 1 | 0.94 | 3.25 | 0.60 | 3.63 | 1.31 (1.05 to 1.63) | *†† | |
| All deaths | | 1 | 0.82 | 1.06 | 0.96 | 1.29 | 1.08 (1.00 to 1.16) | * | | 1 | 0.73 | 1.23 | 0.85 | 1.45 | 1.11 (1.00 to 1.22) | * | |
| | | | | | | | | | | | | | | | | | |

CHD=coronary heart disease. See footnote to table 1 for P values.

Table 5 Age adjusted hazard ratios by fifths of metabolic and haemostatic factors

| | | | | | Men | | | | Women | | | | | | | | |
|----------------|---------------|--------|-------|-------|-------|-------|-------------------------------------|---------|-------|-------|-------|-------|-------|-------|----------------------------------|---------|--|
| Centile 1 | 1 | 20 | 40 | 60 | 80 | 99 | Missing | | 1 | 20 | 40 | 60 | 80 | 99 | Missing | | |
| Fifth | | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | |
| Total serum ch | nolesterol (m | mol/l) | | | | | | | | | | | | | | | |
| | 3.96 | 5.41 | 6.01 | 6.56 | 7.31 | 9.44 | 424 | | 3.98 | 5.47 | 6.16 | 6.80 | 7.65 | 10.25 | 733 | | |
| All CHD | | 1 | 1.13 | 2.05 | 2.15 | 3.15 | 1.34 (1.34 to 1.44) | *** | | 1 | 2.43 | 2.97 | 3.51 | 3.94 | 1.28 (1.12 to 1.45) | *** | |
| CHD deaths | | 1 | 1.14 | 1.50 | 1.74 | 2.21 | 1.23 (1.09 to 1.38) | *** | | 1 | 1.10 | 3.23 | 1.87 | 2.27 | 1.14 (0.88 to 1.48) | NS | |
| All deaths | | 1 | 0.88 | 1.04 | 0.93 | 1.13 | 1.03 (0.96 to 1.11) | NS | | 1 | 0.83 | 1.00 | 0.73 | 0.86 | 0.96 (0.86 to 1.07) | NS | |
| HDL cholester | ol (mmol/l) | | | | | | | | | | | | | | | | |
| | 0.68 | 1.06 | 1.23 | 1.40 | 1.64 | 2.43 | 676 | | 0.86 | 1.32 | 1.54 | 1.74 | 2.00 | 2.90 | 926 | | |
| All CHD | | 1 | 0.65 | 0.54 | 0.42 | 0.40 | 0.79 (0.73 to 0.85) | *** | | 1 | 0.59 | 0.44 | 0.35 | 0.22 | 0.69 (0.61 to 0.78) | *** | |
| CHD deaths | | 1 | 0.71 | 0.65 | 0.43 | 0.44 | 0.80 (0.71 to 0.91) | *** | | 1 | 0.87 | 0.53 | 0.53 | 0.32 | 0.76 (0.60 to 0.97) | * | |
| All deaths | | 1 | 0.81 | 0.91 | 0.81 | 0.82 | 0.95 (0.88 to 1.02) | NS | | 1 | 0.74 | 0.59 | 0.35 | 0.71 | 0.87 (0.78 to 0.97) | *† | |
| Serum triglyce | rides (mmol/ | 1) | | | | | | | | | | | | | | | |
| | 0.57 | 1.23 | 1.68 | 2.30 | 3.25 | 7.27 | 430 | | 0.50 | 0.91 | 1.22 | 1.59 | 2.23 | 5.55 | 735 | | |
| All CHD | | 1 | 1.48 | 1.65 | 2.11 | 2.25 | 1.21 (1.12 to 1.30) | *** | | 1 | 2.21 | 1.86 | 3.90 | 5.23 | 1.46 (1.28 to 1.67) | *** | |
| CHD deaths | | 1 | 1.69 | 1.36 | 2.18 | 1.70 | 1.13 (1.00 to 1.27) | * | | 1 | 3.50 | 4.11 | 5.25 | 6.21 | 1.33 (1.01 to 1.74) | * | |
| All deaths | | 1 | 1.29 | 0.79 | 1.27 | 1.20 | 1.03 (0.96 to 1.12) | † | | 1 | 1.01 | 1.24 | 1.50 | 1.61 | 1.15 (1.02 to 1.29) | * | |
| Blood glucose | (mmol/l) | | | | | | | | | | | | | | | | |
| | 3.28 | 4.35 | 4.69 | 5.02 | 5.54 | 11.24 | 421 | | 3.29 | 2.44 | 4.62 | 4.80 | 5.21 | 9.55 | 731 | | |
| All CHD | | 1 | 1.11 | 0.68 | 0.73 | 1.12 | 0.99 (0.92 to 1.06) | NS†† | | 1 | 1.01 | 0.87 | 0.79 | 1.14 | 1.01 (0.90 to 1.13) | NS | |
| CHD deaths | | 1 | 1.12 | 0.63 | 0.66 | 1.07 | 0.97 (0.86 to 1.09) | NS | | 1 | 1.14 | 0.90 | 0.71 | 1.60 | 1.09 (0.86 to 1.37) | NS | |
| All deaths | | 1 | 0.89 | 0.72 | 0.64 | 0.96 | 0.97 (0.90 to 1.04) | † | | 1 | 0.88 | 0.78 | 0.69 | 1.06 | 1.00 (0.89 to 1.11) | NS | |
| Uric acid (µmo | ol/I) | | | | | | | | | | | | | | | | |
| | 185.6 | 264.2 | 295.7 | 327.4 | 367.3 | 488.2 | 421 | | 127.6 | 193.9 | 221.5 | 248.3 | 285.9 | 426.8 | 730 | | |
| All CHD | | 1 | 1.02 | 1.10 | 0.97 | 1.32 | 1.06 (0.98 to 1.14) | NS | | 1 | 1.17 | 1.20 | 1.10 | 1.54 | 1.09 (0.97 to 1.23) | NS | |
| CHD deaths | | 1 | 0.57 | 1.05 | 0.81 | 1.26 | 1.08 (0.96 to 1.22) | NS | | 1 | 1.71 | 0.58 | 1.48 | 1.84 | 1.14 (0.89 to 1.46) | NS | |
| All deaths | | 1 | 0.96 | 1.01 | 0.95 | 1.16 | 1.03 (0.96 to 1.11) | NS | | 1 | 0.95 | 1.11 | 1.05 | 1.72 | 1.15 (1.03 to 1.29) | * | |
| Plasma fibrino | gen (g/l) | | | | | | | | | | | | | | | | |
| | 1.06 | 1.83 | 2.10 | 2.36 | 2.75 | 4.61 | 659 | | 1.07 | 1.90 | 2.17 | 2.44 | 2.82 | 4.51 | 1015 | | |
| All CHD | | 1 | 1.21 | 1.30 | 1.30 | 2.16 | 1.19 (1.10 to 1.29) | *** | | 1 | 1.59 | 1.66 | 1.91 | 2.70 | 1.24 (1.09 to 1.40) | *** | |
| CHD deaths | | 1 | 1.38 | 1.36 | 1.49 | 3.01 | 1.30 (1.14 to 1.48) | *** | | 1 | 0.88 | 1.39 | 2.15 | 3.42 | 1.45 (1.11 to 1.91) | ** | |
| All deaths | | 1 | 1.40 | 1.34 | 1.56 | 2.59 | 1.25 (1.15 to 1.35) | *** | | 1 | 0.87 | 1.09 | 1.20 | 2.20 | 1.26 (1.12 to 1.41) | *** | |

CHD=coronary heart disease. See footnote to table 1 for P values.

hazard ratios relative to that calculated for the remaining one to four classes. Significance tests were applied both for a linear trend in the logarithm of hazard ratios and for a residual non-linear effect where appropriate. Rather than calculating confidence intervals for each class, we calculated an estimate and 95% confidence limits for the multiplicative constant of risk across consecutive classes. After converting hazard ratios of <1.0 to their reciprocals for protective factors we ranked those for the top class of each factor in bar charts for all coronary heart disease and all deaths, although this meant mixing results for continuous and categorical factors. Complex issues of interaction, confounding, measurement, and causation are deferred to later analyses.

Results

After allowing for wrong addresses, the 11 629 men and women in the Scottish heart health study follow up study were 72% of those originally invited. Numbers at risk and numbers of end points by age and sex are given in table 1. Annual event rates in men were 9.6 per 1000 for all coronary heart disease, 3.7 for coronary heart disease deaths, and 8.9 for all deaths. In women the equivalent rates were 4.0, 1.1, and 4.7.

Tables 2-6 shows the relation of different types of factors to the risk of the three end points. Fuller details of the categories are referenced where necessary.

Housing tenure²⁷—Renters had highly significant excess hazard ratios than owner occupiers for all end points, higher for women than men.

Diabetes mellitus had the same low prevalence of 1.5% in both sexes. A highly significant excess of all

deaths existed in men and of all coronary heart disease in women; other hazard ratios were less significant.

Women who underwent the $menopause^{28}$ before recruitment, after age adjustment, had insignificantly raised hazard ratios.

Current *cigarette smokers*²⁹⁻³² had very highly significant increases in hazard ratios over never smokers for all end points, greater in women.

*Physical inactivity at work*³³ was associated with increased risk for all end points, but the proportion admitting to it was small, particularly in women.

Self reported *leisure physical inactivity*³³ was also associated with significantly increased risks for all end points.

Previous coronary heart disease³⁴ was analysed for four categories compared with those with no evidence of it from their medical history, Rose questionnaire, or electrocardiogram.¹⁸ These were: a positive score on the Rose questionnaire alone; an electrocardiogram positive for ischaemia without a diagnosis; diagnosed angina without myocardial infarction; diagnosed myocardial infarction. Those with past myocardial infarction could not score for non-fatal recurrence, hence the missing cells. Hazard ratios were greatly increased for all categories of coronary heart disease and for all cause mortality.

A high *Bortner score*^{20 35} for type A personality in men showed no significant effect in predicting coronary end points but was significantly protective against all deaths. In women it showed a protective effect for coronary end points too.

Serum cotinine values,²⁹⁻³² measuring exposure to tobacco smoke, showed a two to threefold increase in hazard ratio in men for all end points; hazard ratios in women were even higher.

Alcohol consumption³⁶ differed in dosage between the sexes. In women the large group of abstainers did worst for all end points: alcohol had a very highly significant protective effect against all coronary heart disease. Men showed similar protection against all coronary heart disease. The male risk curve for all deaths was a shallow non-significant "U" shape, with the higher limb in the high consumption group (≥30 units/week), whereas in women the curve was tilted marginally the other way.

Height was significantly protective against all coronary heart disease in both sexes and all deaths in men.

Weight showed a "U" shaped relation to death from all causes in both sexes. For other end points the curve was not significant or was "J" shaped.

Body mass index produced a significant excess risk of all coronary heart disease with obesity but a "U" shaped curve for all deaths, which was shallow in women and non-significant in men.

The mean of the two *systolic blood pressure*³⁷ readings showed highly significant gradients for all end points in both sexes. Gradients were steeper in women.

For *diastolic blood pressure*³⁷ gradients in men were similar to those for systolic pressure, but in women they were somewhat reduced.

The gradient with *total serum cholesterol* concentration³⁸ was very highly significantly positive for all coronary heart disease, weaker for coronary heart disease deaths, and undetectable for all deaths.

By contrast, high density lipoprotein cholesterol concentration showed a protective negative gradient for coronary end points, more marked in women, in whom it also related significantly to all deaths; men also showed a negative tendency, albeit insignificant.

Serum triglyceride concentrations (measured without fasting) showed significant positive gradients for five of the six end points, steeper in women. All deaths in men was the exception.

Blood glucose (measured without fasting) showed shallow insignificant "U" shaped risk curves for all end points in women and significantly non-linear effects for two end points in men.

There seemed to be no general pattern of risk for *uric acid* concentration beyond a slightly raised risk in the highest class for all end points in both sexes.

Plasma fibrinogen^{21 28 39} showed highly significant positive trends in both sexes for all end points.

Sodium excretion⁴⁰ did not predict coronary heart disease in men and showed a borderline negative gradient for all deaths, whereas in women it was just positive for all coronary heart disease.

In contrast, *potassium excretion*⁴⁰ showed a highly significant protective gradient for all deaths in both sexes and significantly protected against all coronary heart disease in men.

Estimated *energy intake*⁴¹ from the food frequency questionnaire showed no significant effects.

Carotenoids⁴² (part of vitamin A) were significantly protective for all coronary heart disease in men.

That finding was even stronger for ascorbic acid¹² (vitamin C).

*Tocopherol*⁴² (vitamin E) intake was just significantly protective for male end points.

Risk factor ranking—Figs 1 and 2 display the ranking in men and women for the different factors for all

Table 6 Age adjusted hazard ratios by fifths of dietary factors

| | | | | Men | | | | Women | | | | | | | |
|----------------|--|---------------------------------------|--|---|---|---|---|--|--|--------|--------|--------|--------|--|---------|
| 1 | 20 | 40 | 60 | 80 | 99 | Missing | | 1 | 20 | 40 | 60 | 80 | 99 | Missing | |
| | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value | | 1 | 2 | 3 | 4 | 5 | Multiplicative constant (95% CI) | P value |
| ion excretion | (mmol/day) | | | | | | | | | | | | | | |
| 46.8 | 129.6 | 168.4 | 204.1 | 251.3 | 416.7 | 1634 | | 37.8 | 98.0 | 123.4 | 149.0 | 187.3 | 319.3 | 1906 | |
| | 1 | 1.18 | 1.11 | 1.26 | 1.23 | 1.05 (0.96 to 1.14) | NS | | 1 | 0.93 | 01.97 | 1.09 | 1.76 | 1.16 (1.00 to 1.33) | * |
| | 1 | 0.96 | 0.62 | 0.97 | 10.92 | 0.98 (0.86 to 1.13) | NS | | 1 | 1.36 | 0.41 | 0.85 | 2.05 | 1.14 (0.87 to 1.49) | NS |
| | 1 | 0.99 | 0.65 | 0.86 | 0.71 | 0.92 (0.84 to 1.00) | BS | | 1 | 0.61 | 0.82 | 0.67 | 0.85 | 0.97 (0.86 to 1.10) | NS |
| m ion excreti | on (mmol/da | ıy) | | | | | | | | | | | | | - |
| 17.6 | 47.2 | 59.5 | 71.3 | 86.3 | 138.1 | 1633 | | 15.3 | 39.7 | 49.4 | 58.5 | 70.2 | 116.4 | 1906 | |
| | 1 | 0.62 | 0.87 | 0.58 | 0.66 | 0.91 (0.83 to 0.99) | * | | 1 | 0.91 | 0.57 | 0.79 | 0.67 | 0.90 (0.79 to 1.04) | NS |
| | 1 | 0.57 | 0.76 | 0.59 | 0.60 | 0.89 (0.77 to 1.03) | NS | | 1 | 0.73 | 0.51 | 0.62 | 0.45 | 0.83 (0.63 to 1.10) | NS |
| | 1 | 0.57 | 0.58 | 0.58 | 0.45 | 0.84 (0.77 to 0.92) | *** | | 1 | 0.74 | 0.86 | 0.48 | 0.41 | 0.81 (0.81 to 0.92) | ** |
| ntake (kcal/da | y) | | | | | | | | | | | | | | |
| 1174 | 1845 | 2148 | 2433 | 2802 | 4135 | 12 | | 812 | 1380 | 1611 | 1834 | 2107 | 3142 | 18 | |
| | 1 | 1.04 | 1.01 | 0.89 | 0.85 | 0.95 (0.89 to 1.02) | NS | | 1 | 1.05 | 0.80 | 0.84 | 1.23 | 1.03 (0.91 to 1.14) | NS |
| | 1 | 0.90 | 0.69 | 1.01 | 0.77 | 0.96 (0.86 to 1.07) | NS | | 1 | 0.69 | 0.53 | 0.94 | 0.75 | 0.97 (0.79 to 1.19) | NS |
| | 1 | 0.82 | 0.86 | 1.10 | 1.07 | 1.04 (0.97 to 1.12) | NS | | 1 | 1.01 | 0.97 | 0.95 | 1.38 | 1.07 (0.97 to 1.18) | NS |
| e (mg/day) | | | | | | | | | | | | | | | |
| 0.12 | 1.51 | 2.04 | 3.27 | 4.64 | 10.06 | 319 | | 0.16 | 1.59 | 2.94 | 3.35 | 4.74 | 10.12 | 224 | - |
| | 1 | 1.11 | 1.03 | 0.73 | 01.70 | 0.90 (0.84 to 0.96) | ** | | 1 | 0.75 | 1.07 | 0.73 | 0.89 | 0.97 (0.87 to 1.08) | NS |
| | 1 | 1.09 | 1.26 | 0.87 | 0.87 | 0.95 (0.85 to 1.07) | NS | | 1 | 0.54 | 1.32 | 0.87 | 0.93 | 1.01 (0.82 to 1.24) | NS |
| | 1 | 1.11 | 0.99 | 0.95 | 0.93 | 0.97 (0.90 to 1.04) | NS | | 1 | 0.83 | 0.87 | 0.81 | 0.96 | 0.99 (0.90 to 1.09) | NS |
| ake (mg/day) | 1 | | | | | | | | | | | | | | |
| 14.9 | 34.7 | 44.2 | 54.5 | 70.2 | 116.1 | 50 | | 10.9 | 30.5 | 42.1 | 55.2 | 72.3 | 118.5 | 30 | - |
| | 1 | 0.87 | 0.83 | 0.63 | 0.52 | 0.85 (0.80 to 0.91) | *** | | 1 | 0.59 | 0.85 | 0.81 | 0.56 | 0.92 (0.82 to 1.02) | BS |
| | 1 | 0.98 | 1.03 | 0.86 | 0.72 | 0.93 (0.83 to 1.04) | NS | | 1 | 1.17 | 2.12 | 1.61 | 0.76 | 0.99 (0.81 to 1.21) | NS |
| | 1 | 1.09 | 1.00 | 0.87 | 0.85 | 0.95 (0.88 to 1.02) | NS | | 1 | 0.98 | 0.79 | 1.03 | 0.72 | 0.95 (0.86 to 1.04) | NS |
| e (mg/day) | | | | | | | | | | | | | | | |
| 2.2 | 4.0 | 5.1 | 6.3 | 9.0 | 27.4 | 51 | | 1.9 | 3.5 | 4.4 | 5.4 | 7.8 | 23.7 | 32 | |
| | 1 | 0.88 | 0.72 | 0.76 | 0.79 | 0.94 (0.87 to 1.00) | BS | | 1 | 0.79 | 0.71 | 0.75 | 0.75 | 0.94 (0.84 to 1.04) | NS |
| | 1 | 0.76 | 0.75 | 0.58 | 0.67 | 0.89 (0.80 to 1.00) | * | | 1 | 0.87 | 1.10 | 0.37 | 1.06 | 0.96 (0.78 to 1.18) | NS |
| | 1 | 0.81 | 0.86 | 0.64 | 0.76 | 0.92 (0.86 to 0.99) | * | | 1 | 1.30 | 1.18 | 1.12 | 0.94 | 0.97 (0.88 to 1.07) | NS |
| | m ion excretion 46.8 m ion excreti 17.6 take (kcal/da 1174 e (mg/day) 0.12 ake (mg/day) 14.9 | 1 1 1 1 1 1 1 1 1 1 | take (kal/day) 1176 1848 2148 1 10.96 1 0.99 1 10.62 1 10.57 1 0.57 1 0.57 1 0.57 1 0.57 1 10.40 1 10 | 1 2 3 3 3 3 3 3 3 3 3 | 1 20 40 50 80 1 2 3 4 on excretion (mmol/day) 46.8 129.6 168.4 204.1 251.3 1 1.18 1.11 1.26 1 0.96 0.62 0.97 1 0.99 0.65 0.86 m ion excretion (mmol/day) 17.6 47.2 59.5 71.3 86.3 1 0.62 0.87 0.58 1 0.57 0.76 0.59 1 0.57 0.76 0.59 1 0.57 0.76 0.59 1 0.57 0.76 0.59 1 0.57 0.76 0.59 1 0.57 0.76 0.59 1 0.57 0.76 0.59 1 0.57 0.58 0.58 take (kcal/day) 1174 1845 2148 2433 2802 1 1.04 1.01 0.89 1 0.90 0.69 1.01 2 0.80 1.00 3 (mg/day) 0.12 1.51 2.04 3.27 4.64 1 1.11 1.03 0.73 3 (mg/day) 1 1.09 1.26 0.87 2 0.86 0.87 3 (mg/day) 1 0.97 0.83 0.63 3 (mg/day) 1 0.98 0.83 0.63 3 (mg/day) 1 0.98 0.83 0.63 4 0.98 0.90 0.88 1 0.98 0.90 0.88 2 0.90 0.90 0.90 2 0.90 0.90 0.90 3 0.90 0.90 0.90 4 0.90 0.90 4 0.90 0.90 4 0.90 0.90 4 0.90 0.90 4 0.90 0.90 4 0.90 0.90 4 0.9 | 1 20 40 60 80 99 1 2 3 4 5 on excretion (mmol/day) 46.8 129.6 168.4 204.1 251.3 416.7 1 1.96 0.62 0.97 10.92 1 0.99 0.65 0.86 0.71 m ion excretion (mmol/day) 0.99 0.65 0.86 0.71 1 0.99 0.65 0.86 0.71 m ion excretion (mmol/day) 0.62 0.97 10.92 17.6 47.2 59.5 71.3 86.3 138.1 18.0 1 0.57 0.76 0.59 0.60 1 0.57 0.58 0.58 0.45 take (kcal/day) 1 1.04 1.01 0.89 0.85 1 1.04 1.01 0.89 0.85 1 1.04 1.01 0.89 0.85 1 0.90 | 1 20 40 60 80 99 Missing 1 2 3 4 5 Multiplicative constant (95% Ct) on excretion (mmol/day) 46.8 129.6 168.4 204.1 251.3 416.7 1634 1 1.18 1.11 1.26 1.23 1.05 (0.96 to 1.14) 1 0.96 0.62 0.97 10.92 0.98 (0.86 to 1.13) 1 0.99 0.65 0.86 0.71 0.92 (0.84 to 1.00) m ion excretion (mmol/day) 1 0.62 0.87 0.58 0.66 0.91 (0.83 to 0.99) 1 0.65 0.86 0.58 0.66 0.91 (0.83 to 0.99) 1 0.57 0.76 0.59 0.60 0.89 (0.77 to 1.03) 1 0.57 0.58 0.58 0.45 0.84 (0.77 to 0.92) take (kcal/day) 1174 1845 2148 2433 2802 4135 12 1 1.04 1.01 0.89 0.85 0.95 (0.89 to 1.02) 1 1 0.82 0.86 1.10 0.77 0.96 (0.86 to 1.07) 2 1 1 0.82 0.86 1.10 0.77 0.96 (0.86 to 1.07) 3 (mg/day) 0.12 1.51 2.04 3.27 4.64 10.06 319 1 1.11 1.09 1.26 0.87 0.87 0.87 0.95 (0.85 to 1.07) 4 1 1.11 0.99 0.95 0.93 0.97 (0.90 to 1.04) ake (mg/day) 14.9 34.7 44.2 54.5 70.2 116.1 50 14 0.88 0.83 0.86 0.72 0.83 0.85 0.95 (0.88 to 1.02) ake (mg/day) 2 2 4.0 5.1 6.3 9.0 27.4 51 1 0.88 0.72 0.76 0.79 0.94 (0.87 to 1.02) a (mg/day) 2 2 4.0 5.1 6.3 9.0 27.4 51 1 0.88 0.72 0.76 0.79 0.94 (0.87 to 1.02) a (mg/day) 2 2 4.0 5.1 6.3 9.0 27.4 51 1 0.88 0.72 0.76 0.79 0.94 (0.87 to 1.00) a (mg/day) | 1 20 40 60 80 99 Multiplicative constant (95% CI) P value on excretion (mmol/day) 46.8 129.6 168.4 204.1 251.3 416.7 1634 1 1.18 1.111 1.26 1.23 1.05 (0.96 to 1.14) NS 1 0.96 0.62 0.97 10.92 0.98 (0.86 to 1.13) NS 1 0.99 0.65 0.86 0.71 0.92 (0.84 to 1.00) BS m ion excretion (mmol/day) 1 0.99 0.65 0.86 0.71 0.92 (0.84 to 1.00) BS m ion excretion (mmol/day) 1 0.62 0.87 0.58 0.66 0.91 (0.83 to 0.99) * 17.6 47.2 59.5 71.3 86.3 138.1 1633 18.6 1 0.67 0.58 0.66 0.91 (0.83 to 0.99) * 19.0 1.05.7 0.76 0.59 0.60 0.89 (0.77 to 1.03) NS 1174 1845 <t< td=""><td> 1 20 40 60 80 99 Missing 1 </td><td> 1 20</td><td> 1 20</td><td> 1 20</td><td> 1 20</td><td> 1 20 40 60 80 99 Missing 1 20 40 60 80 99 Missing 1 20 40 60 80 99 99 10 10 10 10 10 1</td><td> 1 20</td></t<> | 1 20 40 60 80 99 Missing 1 | 1 20 | 1 20 | 1 20 | 1 20 | 1 20 40 60 80 99 Missing 1 20 40 60 80 99 Missing 1 20 40 60 80 99 99 10 10 10 10 10 1 | 1 20 |

CHD=coronary heart disease. See footnote to table 1 for P values.




Fig 3 Age adjusted hazard ratios (and 95% confidence limits) for all coronary heart disease events by fifths of total cholesterol in men and women (lowest fifth=1)

coronary heart disease and for all deaths, in descending order of hazard ratios for the top class. Harmful factors have a plus sign. For protective factors (minus sign) the reciprocal was used.

Discussion

Our 27 factors cover the full range of classical and candidate factors included when the Scottish Heart Health Study was planned, but to prevent overload we chose single exemplars for social status²⁷ ⁴³ and tobacco smoke inhalation,29 32 restricted diet to six factors, and left fat biopsy analyses for later. The three end points are also a subset. Early cohort studies emphasised first development of coronary heart disease,1 4 but table 3 shows that over 20% of the participants had evidence of coronary heart disease when seen, and 8.2% of men and 5.0% of women had been already diagnosed. We found similar risk factor rankings to those in fig 1 in people with no evidence or history of previous coronary heart disease but the number of end points was halved. The total study population is relevant to reality, where middle aged people are at all stages of coronary heart disease but the same risk factors operate across them. Our results emphasise that existing coronary heart disease is the most powerful of its own predictors—and therefore the importance of secondary prevention. Death from coronary heart disease provides a specific, severe end point linking all coronary heart disease with all deaths, the ultimate arbiter.

Failure of some coronary risk factors to predict all cause mortality has been explained previously by separating early from late deaths.⁴⁴ Our results for four and eight years were similar. Alternatives to the Cox model²⁶ produced similar findings, showing that our results are robust.

We have not preselected risk factors by results. Twenty seven of our own and others' favourite factors were entered as starters, without bias, handicap, or disqualification, into three competitions for rankings run in parallel in each sex.

Men and women, coronary end points and all cause mortality

Results of comparing men and women are illustrated in fig 3, which shows confidence limits for hazard ratios in the different fifths of total cholesterol concentration. Limits were wider in women, as the numbers of end points were smaller, but the extremes of risk, as in many factors, appeared greater. Risk overall is lower in women so a larger hazard ratio may conceal a smaller excess risk between top and bottom fifth, a situation analogous to the effect of age in factors such as smoking, where relative risk is very high in young people, in whom risk is low.⁴⁵ Rankings used in the figures, based on the extreme classes, and the multiplicative constant between adjoining classes, both summarise the results. The tables sometimes suggest other complex distributions and thresholds not simply summarised. Comprehensive ranking of factors in figs 1 and 2 was feasible only by mixing together the categorical factors with continuous ones.

Men and women show different rankings for the factors but considerable agreement. For all coronary heart disease the same eight factors appear in the top 12 for both sexes, for coronary heart disease death the same nine, and for all deaths the same 10-which is surprising in view of the heterogeneity in cause of death between men and women. Random variation could account for much of the differences in ranking between the sexes. It would be reduced with larger numbers. The multiplicative constants in tables 2-6 are often very close, and their confidence limits overlap. When we tested the hazard ratios for evidence of differences between the two sexes a few were of borderline statistical significance, but the most extreme was the Bortner score, which is ranked 11th in women and 26th in men for all coronary heart disease, a finding consistent with reported sex differences in responses.46

Association, causation, interaction, confounding, and regression dilution

Observational epidemiological studies are better placed to show association than causation. Early disease may change factors so that associations are concealed or causation reversed. Factors may be associated sufficiently closely to cause confounding⁴⁷ and lack of independence. Difficulties of measurement and within person variability may conceal or minimise true effects—so called regression dilution.⁴⁸ There may be a threshold. High ranking of a factor does not guarantee causation, nor low rank lack of it.

Nevertheless, the strength of associations, or hazard ratios, is important evidence for causation. The associations help show relevance in a British population targeted for change whose pattern of risk factors overlaps that in many industrialised countries. Our results emphasise the importance of coronary heart disease itself as a marker for risk warranting intervention, and also that of the classical coronary risk factors in coronary heart disease risk. Reasons why other factors have done unexpectedly well or badly warrant investigation both within the dataset of the Scottish Heart Health Study and elsewhere, as do the discrepancies between risk factors for coronary heart disease and all cause mortality.

We thank the 300 general practitioners and the survey nurses, technicians, data clerks, and research assistants; the agencies for providing death certificates and data on hospital admissions; other past contributors (referenced coauthors); and, above all, 11 629 men and women across Scotland who willingly participated.

Key messages

- Among Scottish men and women studied for 27 risk factors for coronary heart disease and followed up for eight years classical risk factors scored strongly in predicting coronary risk but the performance of new ones was more variable
- Risk factors for coronary disease, and also for death, showed few, albeit interesting, differences between men and women
- Relative risk was often higher for risk factors in women but they had low levels of absolute risk when risk factor levels were low
- Smoking, blood pressure, and fibrinogen predicted coronary disease and also death, but other factors are less consistent
- Unifactorial results should not be overinterpreted, but the protective effect of potassium consumption is of particular interest

Funding: Scottish Office, British Heart Foundation, and BUPA (an earlier version of this paper, confined to coronary end points won the 1996 BUPA epidemiology prize).

Conflict of interest: None.

- Dawber TR. The Framingham study. The epidemiology of atherosclerotic disease. Cambridge MA: Harvard University Press, 1980 Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary
- risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 1992;339:702-6.
- Rich-Edwards JW, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. Height and the risk of cardiovascular disease in women. AmJEpidemiol 1995:142:909-17.
- Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report on the Pooling Project. *J Chron Dis* 1978;31:201-6.
- Keys A. Seven countries: a multivariate analysis of death and coronary heart
- disease. Cambridge, MA: Harvard University Press, 1980. Shaper AG, Pocock SJ, Walker M, Phillips AM, Whitehead TP, Macfarlane PW. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. *J Epidemiol Community Health* 1985;39:197-
- Sweetnam PM, Bolton CH, Yarnell JW, Bainton D, Baker IA, Elwood PC, et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Studies. 1994;90:769-74.
- Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. *Lancet* 1993;342:1076-9.
- Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. *JAMA* 1992;267;70-6.
- 10 WHO MONICA Project, prepared by Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in 4 continents. *Circulation* 1994;90:583-612.
- World health statistics annual 1995. Geneva: WHO, 1996
- 12 Smith WCS, Crombie IK, Tavendale R, Irving JM, Kenicer MB, Tunstall-Pedoe H. The Scottish Heart Health Study: objectives and development of methods. Health Bull 1987;45:211-17.
- 13 Smith WCS, Tunstall-Pedoe H, Crombie IK, Tavendale R. Concomitants of excess coronary deaths major risk factor and lifestyle findings from 10,359 men and women in the Scottish Heart Health Study. Scot Med J 1989:34:550-5
- Tunstall-Pedoe H, Smith WCS, Crombie IK, Tavendale R. Coronary risk factor and lifestyle variation across Scotland: results from the Scottish Heart Health Study. *Scot Med J* 1989;34:556-60. 15 Crombie IK, Smith WCS, Tavendale R, Tunstall-Pedoe H. Geographical
- clustering of risk factors and lifestyle for coronary heart disease in the Scottish Heart Health Study. *Br Heart J* 1990;64:199-203.
- Scottish Heartt Health Study. Br Heart J 1990;04:199-205.
 Crombie IK, Smith WCS, Irving JM, Tunstall-Pedoe H. Experience with general practitioner lists as a sampling frame for a survey of cardiovascular risk factors. Statistician 1989;38:25-31.
 WHO MONICA Project Principal Investigators (prepared by Tunstall-Principal Investigators).
- Pedoe H). The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): a major international collaboration. *J Clin Epidemiol* 1988;41:105-14.
- 18 Rose GA, Blackburn H, Gillum RF, Prineas RJ: Cardiovascular survey methods. Geneva: World Health Organisation, 1982.

- 19 Yarnell JWG, Fehily AM, Milbank ME, Sweetnam PM, Walker CC. A short dietary questionnaire for use in epidemiological surveys: a comparison with weighed records. *Hum Nutr:Appl Nutr* 1983;37:103-12.
- 20 Bortner RW. A short rating scale as a potential measure of pattern A behaviour. J Chron Dis 1969;22:87-91
- 21 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990;43[:]913-9.
- 22 WHO MONICA Project: MONICA manual (revised edition). Geneva: World Health Organisation, 1990.
- 23 Prineas RJ, Crow R.S, Blackburn H: The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Bristol: John Wright, 1982.
- Kendrick S, Clarke J. The Scottish record linkage system. Health Bull 1993.51:72-79.
- 25 Tunstall-Pedoe H, Morrison C, Woodward M, Fitzpatrick B, Watt G. Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 91: presentation, diagnosis, treatment and 28 day case fatality of 3991 events in men and 1551 events in women. *Circulation* 1996;93:1981-92.
- 26 Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994
- 27 Woodward M, Shewry MC, Smith WCS, Tunstall-Pedoe H. Social status and coronary heart disease: results from the Scottish Heart Health Study. Prev Med 1992;21:136-48.
- 28 Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, menopause and hormone replacement therapy. *Br J Haematol* 1993;83:616-21.
 29 Woodward M, Tunstall-Pedoe H, Smith WCS, Tavendale R. Smoking
- characteristics and inhalation biochemistry in the Scottish population. Clin Epidemiol 1991;44:1405-10.
- 30 Tunstall-Pedoe H, Woodward M, Brown CA. Tea drinking, passive smoking, smoking deception and serum cotinine in the Scottish Heart Health Study. *J Clin Epidemiol* 1991;44:1411-4.
- Woodward M, Tunstall-Pedoe H. Self titration of nicotine: evidence from the Scottish Heart Health Study. Addiction 1993;88:821-30.
- 32 Tunstall-Pedoe H, Brown CA, Woodward M, Tavendale R. Passive smoking by self report and serum cotinine and the prevalence of respiratory and coronary heart disease in the Scottish Heart Health Study. Epidemiol Community Health 1995;49:139-43.
- 33 Crombie IK, Lee AJ, Smith WCS, Tunstall-Pedoe H. Levels and social patterns of self reported physical activity in Scotland. Health Ed J . 1990:49:71-4.
- Smith WCS, Kenicer MB, Tunstall-Pedoe H, Clark EC, Crombie IK. Prevalence of coronary heart disease in Scotland: Scottish Heart Health Study. Br Heart J 1990;64:295-8.
- Woodward M, Shewry MC, Smith WCS, Tunstall-Pedoe H. Coronary heart disease and socioeconomic factors in Edinburgh and north Glasgow. Statistician 1990;39:319-29.
- 36 Woodward M, Tunstall-Pedoe H. Alcohol consumption, diet, coronary risk factors and prevalent coronary heart disease in men and women in the Scottish Heart Health Study. J Epidemiol Community Health 1995:49:354-62.
- 37 Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. BMJ 1990;300:981-3.
- Tunstall-Pedoe H, Smith WCS, Tavendale R. How-often-that-high graphs of serum cholesterol. Findings from the Scottish Heart Health and Scot-
- tish MONICA studies. *Lancet* 1989;i:540-2. 39 Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br Heart J 1993;69:338-42.
- 40 Smith WCS, Crombie IK, Tavendale RT, Gulland SK, Tunstall-Pedoe H. Urinary electrolyte excretion, alcohol consumption, and blood pressure in the Scottish heart health study. BMJ 1988;297:329-30.
- Bolton Smith C, Woodward M, Tunstall-Pedoe H. The Scottish Heart Health Study. Dietary intake by food frequency questionnaire and odds ratios for coronary heart disease risk. I. The macronutrients. Eur J Clin Nutr 1992;46:75-84.
- 42 Bolton Smith C, Woodward M, Tunstall-Pedoe H. The Scottish Heart Health Study. Dietary intake by food frequency questionnaire and odds ratios for coronary heart disease risk. II. The antioxidant vitamins and fibre. Eur J Clin Nutr 1992;46:85-93.
- 43 Morrison C, Woodward M, Leslie W, Tunstall-Pedoe H. Effect of socioeeconomic group on incidence of, management of, and survival after myocardial infarction and coronary death: analysis of community coronary event register. BMJ 1997;314:541-6.
- 44 Rose G, Shipley M. Plasma lipids and mortality: a source of error. Lancet 1980;i:523-6
- $45\ \ Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, et al. Cigarette$ smoking, tar yields and non fatal myocardial infarction in 14 000 cases and 32 000 controls in the United Kingdom. BMJ 1995;311:471-7.
- 46 Knox SS, Follmann D. Gender differences in the psychosocial variance of
- Framingham and Bortner Type A measures. *J Psychosom Res* 1993;709-16. 47 Smith GD, Phillips AN. Confounding in epidemiological studies: why independent effects may not be all they seem. *BMJ* 1992;305:757-9.
- 48 Hughes MD. Regression dilution in the proportional hazards model. Biometrics 1993;49: 1056-66.
- 49 The WHO MONICA Project: a worldwide monitoring system for cardiovascular diseases. WHO statistics annual 1989. Geneva: World Health Organisation, 1989: 27-139.

(Accepted 17 June 1997)